Ron Milo

Barzilai Medical Center — Israel

Medicine · Health Sciences

32h-index4.7kcitations105works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(38), Immunotherapy and Immune Responses(14), T-cell and B-cell Immunology(12), Peripheral Neuropathies and Disorders(9), Palliative Care and End-of-Life Issues(6)

Publications104 total

The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis
PLoS Biology·2025Open Access
Climate change velocity at constant elevation is tenfold greater than earlier unconstrained estimates
2025Open Access
Revisiting Earth’s Seasonality using Machine Learning Models
2025Open Access
Revisiting Earth’s Seasonality using Machine Learning Models
2025Open Access
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Neurology and Therapy·2023· 39 citedOpen Access
Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group Viewpoint
Journal of Neurology·2023· 3 cited
The consequences of switching from Gilenya® to generics for fingolimod
Multiple Sclerosis and Related Disorders·2023· 4 cited
B cell targeted therapies in inflammatory autoimmune disease of the central nervous system
Frontiers in Immunology·2023· 32 citedOpen Access
Genetic <scp>Creutzfeldt‐Jakob</scp> disease in Turkish Jews—demographic and clinical features
Acta Neurologica Scandinavica·2022· 2 cited
Protection against omicron severe disease 0-7 months after BNT162b2 booster
2022· 1 citedOpen Access
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001)
Neurology·2022
The Global Mass and Average Rate of Rubisco
2022· 3 citedOpen Access
Protection by 4th dose of BNT162b2 against Omicron in Israel
2022· 28 citedOpen Access
Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage
Journal of the Neurological Sciences·2021· 11 cited
The development and use of the European academy of neurology guideline on palliative care in advanced progressive multiple sclerosis
Journal of the Neurological Sciences·2021
The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5
Nature Communications·2021· 73 citedOpen Access
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals
Multiple Sclerosis and Related Disorders·2021· 10 cited
Association between cervical disc disease and lesions of multiple sclerosis
The Neuroradiology Journal·2021· 4 citedOpen Access
Palliative care in multiple sclerosis: European guideline
Multiple Sclerosis Journal·2020· 3 citedOpen Access
EAN guideline on palliative care of people with severe, progressive multiple sclerosis
European Journal of Neurology·2020· 44 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Hillel Panitch(6), Nicole Kerlero de Rosbo(4), Olaf Stüve(4), Esther Kahana(3), Avraham Ben‐Nun(3), Ludwig Kappos(3), Heinz Wiendl(3), Amos D. Korczyn(3), Alessandra Solari(3), Andrea Giordano(3), Jaume Sastre‐Garriga(3), Sascha Köpke(3), Anne Christin Rahn(3), Ingo Kleiter(3), Mario Alberto Battaglia(3), Jette Bay(3), Jelena Drulović(3), Liesbeth Kooij(3), John Mens(3), Ivan Milanov(3)